ASP Isotopes Inc. Hosts Investor Access Event in South Africa Providing Updates on its Silicon-28, Ytterbium-176 and Carbon-14 Facilities
ASP Isotopes (NASDAQ: ASPI) is hosting a two-day investor access event in Pretoria, South Africa, welcoming 27 investors from 9 countries. The company has achieved significant breakthroughs with its Quantum Enrichment (QE) technology, demonstrating an enrichment factor of up to 678, substantially higher than previous expectations of 50 and other laser-based approaches which achieve less than 20.
The company announced accelerated commissioning of its Silicon-28 and Ytterbium-176 facilities, with commercial production now expected in Q1 2025, ahead of previous H1 2025 timeline. The first shipment of Carbon-14 feedstock is expected to arrive in January, with a second shipment in February/March, enabling commercial production and sales in H1 2025.
Additionally, ASPI granted restricted stock awards covering 275,000 shares to two new non-executive employees, vesting over four years in eight semi-annual installments.
ASP Isotopes (NASDAQ: ASPI) sta ospitando un evento di accesso per investitori di due giorni a Pretoria, in Sudafrica, accogliendo 27 investitori provenienti da 9 paesi. L'azienda ha raggiunto risultati significativi con la sua tecnologia di arricchimento quantistico (QE), dimostrando un fattore di arricchimento fino a 678, ben superiore alle aspettative precedenti di 50 e ad altri approcci basati su laser che ottengono meno di 20.
L'azienda ha annunciato l'accelerazione della messa in servizio dei suoi impianti di Silicon-28 e Ytterbium-176, con la produzione commerciale ora prevista nel Q1 2025, anticipando la precedente tempistica di H1 2025. La prima spedizione di materie prime di Carbonio-14 è attesa per gennaio, con una seconda spedizione a febbraio/marzo, consentendo la produzione e le vendite commerciali nel H1 2025.
Inoltre, ASPI ha concesso premi in azioni limitate coprendo 275.000 azioni a due nuovi dipendenti non esecutivi, con un periodo di maturazione di quattro anni in otto rate semestrali.
ASP Isotopes (NASDAQ: ASPI) está organizando un evento de acceso para inversionistas de dos días en Pretoria, Sudáfrica, dando la bienvenida a 27 inversores de 9 países. La empresa ha logrado avances significativos con su tecnología de Enriquecimiento Cuántico (QE), demostrando un factor de enriquecimiento de hasta 678, mucho más alto que las expectativas anteriores de 50 y otros enfoques basados en láser que logran menos de 20.
La compañía anunció la aceleración de la puesta en operación de sus instalaciones de Silicon-28 y Ytterbium-176, con la producción comercial ahora esperada para el primer trimestre de 2025, anticipándose a la cronología anterior del primer semestre de 2025. Se espera que el primer envío de materias primas de Carbono-14 llegue en enero, con un segundo envío en febrero/marzo, lo que permitirá la producción y venta comercial en el primer semestre de 2025.
Adicionalmente, ASPI otorgó premios de acciones restringidas que cubren 275,000 acciones a dos nuevos empleados no ejecutivos, con un período de maduración de cuatro años en ocho pagos semestrales.
ASP Isotopes (NASDAQ: ASPI)는 남아프리카 프리토리아에서 이틀간의 투자자 접근 이벤트를 개최하고 있으며, 9개국에서 27명의 투자자를 초대하고 있습니다. 이 회사는 양자 농축(QE) 기술로 중대한 breakthroughs를 이루어냈으며, 678에 이르는 농축 계수를 보여주고 있어 이전의 50 및 20 이하에 도달하는 다른 레이저 기반 접근 방식보다 상당히 높은 수치입니다.
회사는 실리콘-28과 이터븀-176 시설의 빠른 운영을 발표했으며, 상업 생산은 이제 2025년 1분기로 예상되고 있으며, 이전의 2025년 상반기 일정보다 앞섭니다. 탄소-14 원료의 첫 번째 선적이 1월에 도착할 것으로 예상되며, 두 번째 선적은 2월/3월에 이루어져, 2025년 상반기 상업 생산 및 판매를 가능하게 합니다.
또한, ASPI는 두 명의 신규 비전무 직원에게 275,000주에 대한 제한 주식을 수여하였으며, 이 주식은 4년에 걸쳐 8개의 반기 할부로 분할 지급됩니다.
ASP Isotopes (NASDAQ: ASPI) organise un événement d'accès pour investisseurs de deux jours à Pretoria, en Afrique du Sud, accueillant 27 investisseurs de 9 pays. L'entreprise a réalisé des avancées significatives avec sa technologie de Quantum Enrichment (QE), démontrant un facteur d'enrichissement allant jusqu'à 678, bien supérieur aux attentes précédentes de 50 et à d'autres approches basées sur le laser qui obtiennent moins de 20.
L'entreprise a annoncé l'accélération de la mise en service de ses installations de Silicon-28 et Ytterbium-176, avec une production commerciale maintenant prévue pour le premier trimestre 2025, en avance sur le calendrier précédent du premier semestre 2025. La première expédition de matières premières Carbon-14 est attendue pour janvier, avec une deuxième expédition en février/mars, permettant la production et les ventes commerciales au premier semestre 2025.
De plus, ASPI a accordé des attributions d'actions restreintes couvrant 275 000 actions à deux nouveaux employés non exécutifs, avec une acquisition échelonnée sur quatre ans en huit versements semestriels.
ASP Isotopes (NASDAQ: ASPI) veranstaltet ein zwei tägiges Zugangsevent für Investoren in Pretoria, Südafrika, und begrüßt 27 Investoren aus 9 Ländern. Das Unternehmen hat bedeutende Durchbrüche mit seiner Quantum-Enrichment (QE) Technologie erzielt, die einen Anreicherungsfaktor von bis zu 678 zeigt, was erheblich höher ist als die vorherigen Erwartungen von 50 und anderen laserbasierten Ansätzen, die weniger als 20 erreichen.
Das Unternehmen gab die beschleunigte Inbetriebnahme seiner Silicon-28 und Ytterbium-176 Anlagen bekannt, wobei die kommerzielle Produktion nun im ersten Quartal 2025 erwartet wird, was den vorherigen Zeitplan von H1 2025 voranbringt. Die erste Lieferung von Kohlenstoff-14 Rohmaterial wird für Januar erwartet, mit einer zweiten Lieferung im Februar/März, die die kommerzielle Produktion und den Verkauf im H1 2025 ermöglicht.
Darüber hinaus hat ASPI eingeschränkte Aktienvergaben für 275.000 Aktien an zwei neue nicht-executive Mitarbeiter genehmigt, die über vier Jahre in acht halbjährlichen Raten fällig werden.
- Achieved breakthrough enrichment factor of 678, significantly exceeding previous target of 50
- Accelerated timeline for Silicon-28 and Ytterbium-176 commercial production to Q1 2025
- Imminent receipt of Carbon-14 feedstock enabling H1 2025 production and sales
- None.
Insights
The reported enrichment factor of 678 using Quantum Enrichment technology represents a groundbreaking achievement in isotope separation. This 30-fold improvement over traditional AVLIS methods (which achieve factors <20) fundamentally transforms the economics of isotope production. The accelerated timeline for Silicon-28 production is particularly significant for the semiconductor industry, where ultra-pure silicon is essential for quantum computing applications and next-generation chips.
The technology's superior enrichment capabilities could establish ASPI as a dominant player in the $5.3 billion global isotope market. The ability to achieve such high enrichment factors across four different elements demonstrates the platform's versatility and scalability. Think of it like upgrading from a hand-cranked separator to an industrial centrifuge - the efficiency gains are transformative.
The accelerated production timeline for Ytterbium-176 could have substantial implications for cancer treatment availability. This isotope is important for producing Lutetium-177, a radiopharmaceutical used in precision oncology treatments. The higher enrichment factors achieved could significantly reduce production costs and increase accessibility of these life-saving treatments.
The Carbon-14 production progress is equally noteworthy. This isotope is essential for drug development and metabolic studies, with applications in pharmaceutical research and carbon dating. The confirmed feedstock delivery and production timeline provides concrete evidence of ASPI's execution capability in the medical isotope space.
Moving up commercial production to Q1 2025 from H1 2025 for both Silicon-28 and Ytterbium-176 facilities signals strong operational execution and could accelerate revenue recognition by several months. The presence of 27 institutional investors from 9 countries demonstrates significant market interest, particularly notable for a company with a market cap of
The planned joint venture with Necsa for advanced nuclear fuels production represents a strategic expansion into a high-value market segment. The combination of accelerated timelines, superior technology performance and expanding market opportunities suggests potential for significant valuation uplift as commercial production commences.
- This week the Company welcomes a group of institutional investors from around the world to its facilities located in Pretoria, South Africa for a two-day investor access event.
- During the investor access event, the Company intends to show the investors the results achieved from Quantum Enrichment demonstrating an enrichment factor of up to 678, versus previous expectations of greater than 50. This compares to an enrichment factor of less than 20 for other laser-based enrichment approaches.
- Commissioning of the Silicon-28 and Ytterbium-176 facilities is currently running ahead of schedule with commercial production expected to commence during the first quarter of 2025 versus previous expectations of the first half of 2025.
- The first shipment of Carbon-14 feedstock is currently in transit and anticipated to arrive in South Africa in January, with the second shipment expected to arrive in February/March, allowing for expected commercial production of enriched Carbon-14 and sales during the first half of 2025.
WASHINGTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today welcomes a group of 27 investors from 9 different countries to its facilities in South Africa for a two-day investor access event.
The facilities tour will include our Operational Head Office, Research and Development Center, first Quantum Enrichment Laser Isotope Facility (Ytterbium-176), Carbon-14 enrichment facility, multi-isotope enrichment facility (Silicon-28) and PET Labs. Investors will also spend a morning at Pelindaba, the operational base of Necsa (South African Nuclear Engineering Corporation), which is the site where the planned joint venture between ASP Isotopes, Quantum Leap Energy and Necsa expects to construct their first advanced nuclear fuels production facility.
The Company will present to investors the enrichment data that has been achieved to date using Quantum Enrichment (QE), the Company’s laser-based approach to isotope enrichment. QE has delivered enrichment factors of up to 678, which have been achieved on four different elements.
ASP Isotopes uses QE, not AVLIS as its laser-based enrichment approach. During the investor event, management will present data that it believes demonstrates the distinction between Quantum Enrichment and AVLIS.
Published literature suggests that other laser-based approaches for isotope enrichment achieved enrichment factors of less than 20(1)(2). The enrichment factor achieved by QE is up to 30-fold greater and Company management believes that this could lead to production efficiencies significantly greater than anything ever achieved with AVLIS.
The Company will also provide updates on the commissioning phase for both the Silicon-28 and the Ytterbium-176 facilities. We expect to commence commercial production of Silicon-28 and Ytterbium-176 during the first quarter of 2025, compared to previous expectations of the first half of 2025.
The Company is also pleased to announce that it has been informed by its Canadian customer, RC14, that the first shipment of Carbon-14 feedstock is in transit and should arrive in South Africa in January. Assuming the second batch of feedstock arrives in February/March, the Company expects to produce and sell the first enriched Carbon-14 during the first half of 2025.
“The construction and commissioning teams have worked exceptionally hard through December and the holiday period to accelerate the commissioning phase of the Silicon-28 and Ytterbium-176 facilities. Both isotopes are urgently required; Silicon-28 to further advance next generation semiconductors and Yterrbium-176 to further advance oncology treatments that will improve patient outcomes. We look forward to an exciting 2025 with a number of key deliverables anticipated” said Paul Mann, Chairman and Chief Executive Officer of ASP Isotopes and Quantum Leap Energy.
(1) Greenland, Contemporary Physics, vol 31, pages 405-424
(2) Snyder, Science & Global Security, Vol 24, 68-91
Inducement Awards.
In connection with commencing employment, two new non-executive employees of ASP Isotopes Inc. were granted awards of restricted stock covering an aggregate of 275,000 shares of ASP Isotopes Inc.’s common stock, par value
About ASP Isotopes Inc.
ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).
There is a growing demand for isotopes such as Silicon-28 for enabling quantum computing; Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, Lithium-7 and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements relating to the performance and future of the Company’s enrichment technologies, the market demand for Silicon-28 and Ytterbium-176, the commencement of supply of enriched isotopes to customers, and the Company’s planned joint venture with Necsa. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as “believes,” “plans,” “anticipates,” “expects,” “estimates,” “projects,” “will,” “may,” “might,” and words of a similar nature. Examples of forward-looking statements include, among others but are not limited to, statements we make regarding expected operating results, such as future revenues and prospects from the potential commercialization of isotopes, future performance under contracts, and our strategies for product development, engaging with potential customers, market position, and financial results. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including the outcomes of various strategies and projects undertaken by the Company; the potential impact of laws or government regulations or policies in South Africa, the United Kingdom or elsewhere; our reliance on the efforts of third parties; our ability to complete the construction and commissioning of our enrichment plants or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions; contracts, dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; and the competitive nature of our industry. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. This press release includes market and industry data and forecasts that we obtained from internal research, publicly available information and industry publications and surveys. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Unless otherwise noted, statements as to our potential market position relative to other companies are approximated and based on third-party data and internal analysis and estimates as of the date of this press release. We have not independently verified this information, and it could prove inaccurate. Industry and market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data-gathering process and other limitations and uncertainties. In addition, we do not know all of the assumptions regarding general economic conditions or growth that were used in preparing the information and forecasts from sources cited herein. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.
Contacts
Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043
FAQ
What enrichment factor has ASP Isotopes (ASPI) achieved with its Quantum Enrichment technology?
When will ASPI begin commercial production of Silicon-28 and Ytterbium-176?
What is the timeline for ASPI's Carbon-14 production in 2025?
How many investors are attending ASPI's South Africa facility tour in January 2025?
What is the vesting schedule for ASPI's recent restricted stock awards?
